Chronic Respiratory Failure, Exercise Capacity, High-flow Nasal Cannula, Optimal SpO2 Value
Conditions
Keywords
HFNC, 6MWD
Brief summary
The purpose of this study is to compare the exercise capacity between high SpO2 (Minimum SpO2 94-96%) value during pulmonary rehabilitation and low SpO2 (Minimum SpO2 84-86%) value during pulmonary rehabilitation for the patients with chronic respiratory failure receiving long-term oxygen therapy.
Detailed description
In patients with chronic respiratory failure, pulmonary rehabilitation is recognized as an evidence-based treatment in improving exercise capacity, muscle strength, dyspnea, and quality of life. However, optimal SpO2 value during pulmonary rehabilitation in patients with chronic respiratory failure receiving long-term oxygen therapy is unclear. The present study is randomized to compare the effect of exercise capacity between high SpO2 (Minimum SpO2 94-96%) value during pulmonary rehabilitation and low SpO2 (Minimum SpO2 84-86%) value during pulmonary rehabilitation for the patients with chronic respiratory failure receiving long-term oxygen therapy.
Interventions
OTHERHigh-flow nasal cannula
The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
OTHERLow SpO2
Low SpO2
Sponsors
National Hospital Organization Minami Kyoto Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Subjects with chronic respiratory failure receiving long-term oxygen therapy for more than 3 months.
Exclusion criteria
* Subjects with severe cardiovascular disease, liver disease, neurological disease, and renal failure. * Subjects with a history of hospitalization for pneumonia or exacerbation of respiratory failure within the last month. * Subjects with changes in LTOT prescription flow within the last month * Subjects who cannot undergo pulmonary rehabilitation due to severe heart failure, arteriosclerosis obliterans or spinal disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the six-minutes walking distance prior to and following 4 weeks of pulmonary rehabilitation | four weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change in the constant-load exercise test (duration time etc.) prior to and following 4 weeks of pulmonary rehabilitation | four weeks |
| Change in the incremental-exercise test (Maximum load value etc.) prior to and following 4 weeks of pulmonary rehabilitation | four weeks |
| Change in the body composition measured by InBody (muscle mass et.) prior to and following 4 weeks of pulmonary rehabilitation | four weeks |
| Change in the arterial blood gas (PaO2 value etc.) prior to and following 4 weeks of pulmonary rehabilitation | four weeks |
| Change in the six-minutes walking test (lowest SpO2 value etc.) prior to and following 4 weeks of pulmonary rehabilitation | four weeks |
| Change in the nutritional status (body mass index(kg/m2) et.) prior to and following 4 weeks of pulmonary rehabilitation | four weeks |
| Change in the sympathetic activity (Plasma catecholamine et.) prior to and following 4 weeks of pulmonary rehabilitation | four weeks |
| Change in the dyspnea (Modified Borg scale) prior to and following 4 weeks of pulmonary rehabilitation | four weeks |
| Change in the inflammation marker (CRP etc.) prior to and following 4 weeks of pulmonary rehabilitation | four weeks |
Countries
Japan
Contacts
Primary ContactYuichi Chihara
Outcome results
None listed